REPL

Replimune (REPL)

Replimune Group Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:REPL

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2025/01/18	07 : 01	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:REPL	Replimune Group Inc
2025/01/11	06 : 01	GlobeNewswire Inc.	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:REPL	Replimune Group Inc
2025/01/08	22 : 00	GlobeNewswire Inc.	Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials	NASDAQ:REPL	Replimune Group Inc
2024/12/23	22 : 00	GlobeNewswire Inc.	Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference	NASDAQ:REPL	Replimune Group Inc
2024/12/21	07 : 00	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:REPL	Replimune Group Inc
2024/12/19	11 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REPL	Replimune Group Inc
2024/12/17	06 : 48	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:REPL	Replimune Group Inc
2024/12/04	22 : 30	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:REPL	Replimune Group Inc
2024/11/27	22 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:REPL	Replimune Group Inc
2024/11/27	07 : 27	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:REPL	Replimune Group Inc
2024/11/26	22 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:REPL	Replimune Group Inc
2024/11/26	13 : 55	GlobeNewswire Inc.	Replimune Announces Pricing of Upsized Public Offering	NASDAQ:REPL	Replimune Group Inc
2024/11/25	21 : 09	GlobeNewswire Inc.	Replimune Announces Proposed Public Offering	NASDAQ:REPL	Replimune Group Inc
2024/11/22	07 : 26	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:REPL	Replimune Group Inc
2024/11/22	06 : 05	GlobeNewswire Inc.	Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway	NASDAQ:REPL	Replimune Group Inc
2024/11/21	11 : 31	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REPL	Replimune Group Inc
2024/11/21	11 : 30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REPL	Replimune Group Inc
2024/11/20	07 : 16	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:REPL	Replimune Group Inc
2024/11/14	21 : 00	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:REPL	Replimune Group Inc
2024/11/12	22 : 16	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:REPL	Replimune Group Inc
2024/11/12	22 : 00	GlobeNewswire Inc.	Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update	NASDAQ:REPL	Replimune Group Inc
2024/11/10	03 : 00	GlobeNewswire Inc.	Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)	NASDAQ:REPL	Replimune Group Inc
2024/11/09	06 : 01	GlobeNewswire Inc.	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:REPL	Replimune Group Inc
2024/10/30	22 : 15	GlobeNewswire Inc.	Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)	NASDAQ:REPL	Replimune Group Inc
2024/10/17	06 : 15	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:REPL	Replimune Group Inc
2024/10/10	05 : 01	GlobeNewswire Inc.	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:REPL	Replimune Group Inc
2024/10/01	21 : 00	GlobeNewswire Inc.	Replimune to Present at Two Upcoming Investor Conferences	NASDAQ:REPL	Replimune Group Inc
2024/09/15	22 : 45	GlobeNewswire Inc.	Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024	NASDAQ:REPL	Replimune Group Inc
2024/09/09	21 : 00	GlobeNewswire Inc.	Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024	NASDAQ:REPL	Replimune Group Inc
2024/09/06	05 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:REPL	Replimune Group Inc